In contrast to non-small cell lung cancer [9], the relatively low number of MPM cases combined with the low prevalence of drug-targetable EGFR mutations in MPM compromises the investigation and use of selective EGFR inhibitors in the treatment of mesothelioma. Here, EGFR is linked to non-small cell lung carcinoma.